Product logins

Find logins to all Clarivate products below.


Biosimilars | Market Events and Forecast | Ophthalmology | 2023

In 2021, sales of branded biologics in ophthalmology totaled more than $9 billion in the major pharmaceutical markets (United States, EU5, and Japan). Throughout our 2021-2031 forecast period, the reference brands Lucentis (ranibizumab) and Eylea (aflibercept) are set to lose patent protection, and biosimilars will enter the market and erode both patient share and drug prices. We present our forecasts for these key reference brands and their biosimilars by molecule and country / region.

Related Market Assessment Reports

Report
Biosimilars – Current Treatment – Endocrinology
Eli Lilly / Boehringer Ingelheim’s Abasaglar / Basaglar was the first biosimilar / follow-on insulin glargine to launch in Europe and the United States, followed by Sanofi’s Admelog / Insulin…
Report
Diabetic Macular Edema / Diabetic Retinopathy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Diabetic macular edema (DME), a complication of diabetic retinopathy (DR), develops as a result of persistently elevated blood sugar levels and can lead to vision loss or blindness if left…
Report
Biosimilars – Current Treatment – Ophthalmology
The ophthalmology market is relatively new in the field of biosimilars: Samsung Bioepis / Biogen’s ranibizumab biosimilar, Byooviz, was the first MAb biosimilar to launch in the U.S. market in…
Report
Thyroid Eye Disease – Executive Insights – Thyroid Eye Disease | Executive Insights (US)
Report
Biosimilars – Current Treatment – Oncology
In 2019, Amgen / Allergan’s trastuzumab biosimilar Kanjinti and bevacizumab biosimilar Mvasi were the first monoclonal antibody (MAb) biosimilars launched in the United States, followed by…